16667-01-9

Upstream product

• 1076-26-2 1-methyl-2-naphthol 
• 861354-02-1 1-bromo-1-methylnaphthalen-2(1H)-one 
• 57565-13-6 1-chloro-1-methylnaphthalen-2(1H)-one 
• 10035-10-6 hydrogen bromide 
• 64-19-7 acetic acid 
• 1096-84-0 bis(2-hydroxy-1-naphthyl)methane 
• 481071-33-4 6-Bromo-1-[(dimethylamino)methyl]-2-naphthyl acetate hydrochloride 
• 247174-14-7 6-bromo-2-methoxy-1-methyl naphthalene 
• 15231-91-1 6-bromo-naphthalen-2-ol 
• 30518-34-4 6-bromo-1-((dimethylamino)methyl)naphthalen-2-ol 
• 739360-70-4 C₁₅H₁₆BrNO₂ 
• 708-06-5 2-hydroxynaphthalene-1-carbaldehyde 
• 858023-45-7 1-anilino-6-bromo-1-methyl-1H-naphthalen-2-one 
• 861354-01-0 1,6-dibromo-1-methyl-1H-naphthalen-2-one 

Downstream Products

• 6968-28-1 4-bromophthalic acid 
• 247174-14-7 6-bromo-2-methoxy-1-methyl naphthalene 
• 337521-09-2 1-(6-{[tert-butyl(dimethyl)silyl]oxy}-5-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propan-1-ol 
• 337521-12-7 6-(1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-1-methyl-2-naphthol 
• 337521-14-9 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-propyl)-1-methyl-2-naphthyl Trifluoromethanesulfonate 
• 337521-16-1 methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthoate 
• 337522-91-5 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-methyl-2-naphthamide 
• 430472-54-1 methyl-1-(bromomethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)propyl]-2-naphthoate 
• 430472-69-8 7-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)propyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one 
• 430472-50-7 7-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)propyl]-2-methyl-1,2-dihydro-3H-benzo[e]isoindol-3-one 
• 1285532-66-2 7-[(1R)-1-{1-[(4-bromophenyl)sulfonyl]-1H-imidazol-4-yl}-1-hydroxy-2-methylpropyl]-2-methyl-1,2-dihydro-3H-benzo[e]isoindol-3-one 
• 1567351-13-6 3',6-dimethoxy-N-(5-methyl-6-((1-methylpiperidin-4-yl)oxy)naphthalen-2-yl)-[1,1'-biphenyl]-3-carboxamide 

Relevant academic research and scientific papers

Organocatalytic Asymmetric Dearomatization Reaction for the Synthesis of Axial Chiral Allene-Derived Naphthalenones Bearing Quaternary Stereocenters

The highly regio-, diastereo-, and enantioselective dearomatization reaction of 1-substituted 2-naphthols and β,γ-alkynyl-α-imino esters with complete atom economy is disclosed via chiral phosphoric acid catalysis. This protocol provides facile and effici

(PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER

The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising

Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors

Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target for the development of cancer chemotherapeutics. In an effort to develop more efficacious compounds for Hsp90 inhibition, novobiocin analogues were prepared by replacing the central coumarin core with naphthalene, quinolinone, and quinoline surrogates. These modifications allowed for modification of the 2-position, which was previously unexplored. Biological evaluation of these compounds suggests a hydrophobic pocket about the 2-position of novobiocin. Anti-proliferative activities of these analogues against multiple cancer cell lines identified 2-alkoxyquinoline derivatives to exhibit improved activity.

17,20-Lyase inhibitors. Part 4: Design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors

A novel series of naphthylmethylimidazole derivatives and related compounds have been investigated as selective 17,20-lyase inhibitors. Optimization of the substituent at the 6-position on the naphthalene ring was performed to yield a methylcarbamoyl derivative, which exhibited potent inhibitory activity against human 17,20-lyase and promising selectivity (>200-fold) for 17,20-lyase over CYP3A4. Further modifications of the methylcarbamoyl derivative led to the discovery of the corresponding tricyclic compound, which showed highly potent activity against human 17,20-lyase (IC50 19 nM) and good selectivity (>1000-fold) for inhibition of 17,20-lyase over CYP3A4. Additional biological evaluation revealed that the tricyclic compound had potent in vivo efficacy in monkeys and favorable pharmacokinetic profiles when administered in rats. Asymmetric synthesis of the selective tricyclic inhibitor was also achieved using a chiral α-hydroxy ketone.

Substituted naphthyl benzothiophene acids

The present invention relates generally to substituted naphthyl benzothiophene acids and methods of using them

Naphthalene derivatives, their production and use

A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.

Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

This invention provides compounds which act as inhibitors of plasminogen activator inhibitor-1 (PAI-1) of the formula: wherein: R, R1, R2, and R3 are H, alkyl, cycloalkyl, —CH2-(cycloalkyl), alkanoyl, halo, hydr